Topics

Infinity Pharmaceuticals Inc. Company Profile

01:04 EDT 1st April 2020 | BioPortfolio

Infinity is an innovative biopharmaceutical company dedicated to advancing novel medicines for people with cancer. Infinity is advancing IPI-549, a first-in-class, oral immuno-oncology development candidate that selectively inhibits PI3K-gamma, in multiple clinical studies. MARIO-275 is a global, randomized, controlled combination study of IPI-549 combined with Opdivo in I/O naïve urothelial cancer patients for which enrollment is expected to be completed in 2020 with data by mid-2021. MARIO-3 is the first IPI-549 combination study in front-line advanced cancer patients and is evaluating IPI-549 in combination with Tecentriq and Abraxane in front-line TNBC and in combination with Tecentriq and Avastin in front-line RCC and is also expected to complete enrollment in 2020 with initial data expected in 2020. In collaboration with Arcus Biosciences, Infinity is evaluating a checkpoint inhibitor-free, novel combination regimen of IPI-549 plus AB928 (dual adenosine receptor antagonist) plus Doxil in advanced TNBC patients. In 2019 Infinity completed enrollment in MARIO-1, a Phase 1/1b study evaluating IPI-549 as a monotherapy and in combination with Opdivo (nivolumab) in patients with advanced solid tumors including patients refractory to checkpoint inhibitor therapy. Data presented from MARIO-1 to date show that IPI-549 has activity and leads to a reduction in the number of circulating myeloid derived suppressor cells (MDSCs) as both a monotherapy and in combination with Opdivo and additional data is expected in 2020. With these studies Infinity is evaluating IPI-549 in the anti-PD-1 refractory, I/O-naïve, and front-line settings. For more information on Infinity, please refer to Infinity's website at www.infi.com.


News Articles [616 Associated News Articles listed on BioPortfolio]

Infinity enters into $20mm royalty sale agreement with BVF

Infinity Pharmaceuticals Inc. entered into a $20mm non-dilutive royalty financing with its largest shareholder BVF Partners. BVF will realize royalties due Infinity from PellePharm for future sales of...

Infinity Pharmaceuticals to Present Corporate Overview at 38th Annual J.P. Morgan Global Healthcare Conference

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) announced today that Adelene Perkins, Chief Executive Officer and Chair of Infinity Pharmaceuticals, will provide a corporate overview at the 38th Annual...

INFINITY: What's Been Learned About BP Lowering and Cognition?

The INFINITY trial adds insight into the importance of blood pressure as a target in the prevention of white matter hyperintensity progression and dementia. Circulation

Abbott secures expanded FDA approval for Infinity DBS System

Abbott has secured the US Food and Drug Administration (FDA) approval of its new Infinity Deep Brain Stimulation (DBS) system, with expanded indication to include targeting of internal The post Abbot...

Infinity Announces the Date of Its Third Quarter 2019 Financial Results Conference Call and Webcast

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) will host a conference call on Wednesday, October 30, 2019 at 4:30 p.m. ET to review its third quarter 2019 financial results and provide an update on th...

Epizyme Names Infinity’s Jeffery Kutok as Chief Scientific Officer

Epizyme (NASDAQ: EPZM) has appointed Jeffery Kutok as its chief scientific officer to guide the Cambridge, MA-based company’s scientific strategy following the FDA’s approval earlier this ...

Infinity Announces the Date of Its Fourth Quarter and Full Year 2019 Financial Results Conference Call and Webcast

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) will host a conference call on Tuesday, March 3, 2020 at 4:30 p.m. ET to review its fourth quarter and full year 2019 financial results and provide an up...

Abbott sees expanded indication for Infinity, positive Proclaim XR data

The FDA has granted Abbott Laboratories an expanded indication for its Infinity directional deep brain stimulation system to  -More- 

Drugs and Medications [11 Associated Drugs and Medications listed on BioPortfolio]

Ibuprofen [preferred pharmaceuticals inc.]

Ibuprofen Oral Suspension USP, 100 mg/5 mL

Ibuprofen [taro pharmaceuticals u.s.a., inc.]

Ibuprofen Oral Suspension USP, 100 mg/5 mL

Ibuprofen [hi-tech pharmacal co., inc.]

Ibuprofen Oral Suspension, USP 100 mg/5 mL

Ibuprofen [aurobindo pharma limited]

Ibuprofen Oral Suspension USP Rx Only

Carboplatin [sagent pharmaceuticals]

Carboplatin Injection(carboplatin aqueous solution)

PubMed Articles [129 Associated PubMed Articles listed on BioPortfolio]

Mytilidae as model organisms in the marine ecotoxicology of pharmaceuticals - A review.

Growing production and consumption of pharmaceuticals is a global problem. Due to insufficient data on the concentration and distribution of pharmaceuticals in the marine environment, there are no app...

Occurrence and ranking of pharmaceuticals in the major rivers of China.

Residual pharmaceuticals have received widespread attention worldwide due to their continuous release and potential hazard to the environment. As a result of rapid development and a large population, ...

Analysis, occurrence and removal of pharmaceuticals in African water resources: A current status.

Pharmaceuticals are organic compounds used in medicines for alleviation of pain. Since 2017, there has been a steady increase on the availability of information on contamination of water resources cau...

An ultrasensitive electrochemical sensing method for detection of microcystin-LR based on infinity-shaped DNA structure using double aptamer and terminal deoxynucleotidyl transferase.

This study develops a novel electrochemical sensing platform for microcystin-LR (MC-LR) detection. This aptasensor comprises the hybridization of double aptamer to its complementary strand (CS) on the...

Prioritization of pharmaceuticals in water environment in China based on environmental criteria and risk analysis of top-priority pharmaceuticals.

Numerous studies have shown that a wide range of pharmaceuticals are present in the environment and many of their adverse biological effects on the aquatic ecosystem and human health are unknown. Due ...

Clinical Trials [274 Associated Clinical Trials listed on BioPortfolio]

Clinical Evaluation of the Infinity DBS System

The purpose of this post market study is to support the chronic clinical performance of the Infinity Deep Brain Stimulation (DBS) Implantable Pulse Generator (IPG), DBS leads, extensions a...

INFINITY™Total Ankle Replacement Follow-up

Study Title INFINITY™Total Ankle Replacement Follow-up (ITAR) Study Design Prospective, multi-site, multi-year post-market clinical follow-up study Study Group Primary/Unilateral and/or ...

An Open-Label Trial of PEMF Therapy [Provant Infinity Therapy System] for Home Use in Postoperative Pain

A study of the use of the Provant Infinity Therapy System when treatment is administered 30 minutes twice daily for 8-weeks (56 days ± 3 days) at home for postoperative pain.

UK Infinity, Post-Market Clinical Follow-up Study

Study Title UK Post-Market Clinical Follow-Up Of The INFINITY® Total Ankle System Study Design Prospective, multi-site, multi-year post-market clinical follow-up study Study Group Primary...

Multicenter RCT for BIliary Brushing: RX Cytology, BOSTON vs. Infinity®, US Endoscopy

The aim of this prospective national multicenter randomized study is to compare, during an ERCP for VBP stenosis, the sensitivity of two biliary brushes: the INFINITY® vs the RX Cytology ...

Companies [1436 Associated Companies listed on BioPortfolio]

Infinity Pharmaceuticals, Inc.

Infinity is an innovative drug discovery and development company seeking to discover, develop, and deliver to patients best-in-class medicines for difficult-to-treat diseases. Inf...

Infinity Info Systems

Founded in 1987, Infinity Info Systems develops customer relationship management (CRM) and business analytics solutions for clients in the financial, life sciences, business services, media and manufa...

Infinity Pharmaceuticals Inc.

Infinity is an innovative biopharmaceutical company dedicated to advancing novel medicines for people with cancer. Infinity is advancing IPI-549, a first-in-class, oral immuno-oncology development ca...

Infinity Group

Infinity Group is an RMB fund pioneer and the leader in cross border China RMB and dollar private equity funds. It is also the founder of the Infinity IP Bank, the hub for IP deve...

Infinity Technology, Inc

We realize both IT and corporate management play vital roles in the success of an organization, but speak different languages. Infinity Technology, Inc. has crafted everything necessary to unite these...

More Information about "Infinity Pharmaceuticals Inc." on BioPortfolio

We have published hundreds of Infinity Pharmaceuticals Inc. news stories on BioPortfolio along with dozens of Infinity Pharmaceuticals Inc. Clinical Trials and PubMed Articles about Infinity Pharmaceuticals Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Infinity Pharmaceuticals Inc. Companies in our database. You can also find out about relevant Infinity Pharmaceuticals Inc. Drugs and Medications on this site too.

Quick Search

Relevant Topics

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...


Corporate Database Quicklinks



Searches Linking to this Company Record